Xcopri Tablet, Film Coated
Product Images NDC 71699-025

Product Visual Gallery

This gallery contains 22 technical images submitted to the FDA as part of the official labeling for Xcopri (NDC 71699-025). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Sk Life Science, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Cenobamate 01)

Chemical structure of cenobamate, the active ingredient in Xcopri, showing its molecular arrangement including a chlorinated aromatic ring, carbamate group, and tetrazole ring.*

FDA Label Image

Figure 1 (Cenobamate 02)

A bar graph comparing the proportion of patients by percentage reduction in seizure frequency from baseline between placebo and Xcopri 200 mg groups. The x-axis shows seizure frequency reduction categories, and the y-axis shows the proportion of patients in each category. Data highlights differences in patient response between the two groups.*

FDA Label Image

Figure 2 (Cenobamate 03)

A bar chart showing the proportion of patients by percent reduction in seizure frequency from baseline. It compares four groups: Placebo, Xcopri 100 mg, Xcopri 200 mg, and Xcopri 400 mg. The x-axis categories are 'Worse', '0 to <25%', '25 to <50%', '50 to <75%', and '75 to ≤100%' reduction in seizure frequency, while the y-axis indicates the proportion of patients as a percentage.*

FDA Label Image

50 mg 30-count Bottle Label (Cenobamate 04)

Label for Xcopri 50 mg film-coated oral tablets containing cenobamate. The label indicates the product is prescription only, contains 30 tablets, and is manufactured for SK Life Science, Inc. It includes storage instructions and a warning to keep out of reach of children. The label displays the NDC 71699-050-30 and a barcode.*

FDA Label Image

100 mg 30-count Bottle Label (Cenobamate 05)

Label for Xcopri 50 mg film-coated tablets containing cenobamate by SK Life Science, Inc. The label indicates it is a professional sample with 30 tablets. Instructions note to swallow whole without crushing. Storage temperature guidance ranges from 20°C to 25°C with allowed excursions.*

FDA Label Image

150 mg 30-count Bottle Label (Cenobamate 06)

Label for Xcopri 100 mg film-coated tablets containing cenobamate, manufactured by SK Life Science, Inc. The label includes NDC 71699-100-30, a 30-tablet count, and instructions to swallow whole without crushing or chewing. Storage conditions specified are controlled room temperature 20°C to 25°C with excursions 15°C to 30°C, and it emphasizes the need to keep out of reach of children and to receive an accompanying medication guide. A barcode and SK Life Science logo are shown.*

FDA Label Image

200 mg 30-count Bottle Label (Cenobamate 07)

Xcopri 150 mg film-coated tablets label for oral use. The label includes the proprietary name Xcopri with the generic name cenobamate tablets and a red banner highlighting 150 mg strength. It states the package contains 30 tablets and provides storage instructions, manufacturer information for SK Life Science, Inc., and a safety notice to keep out of reach of children. The label also includes dosage guidance and a barcode.*

FDA Label Image

12.5 mg 14-count And 25 mg 14-count Titration Pack Label (Cenobamate 08)

Label for Xcopri (cenobamate) 200 mg film-coated tablets, prescription drug manufactured by SK Life Science, Inc. The label states 30 tablets per package and includes storage instructions and usage warnings. The label shows the NDC 71699-200-30 and features a barcode and SK Life Science logo.*

FDA Label Image

12.5 mg 14-count And 25 mg 14-count Titration Pack Label (Cenobamate 09)

Packaging label for Xcopri (cenobamate tablets) 12.5 mg and 25 mg oral film-coated tablets in a titration pack. The label shows dosage strengths 12.5 mg and 25 mg prominently, with instructions for use as a titration pack. The pack contains 14 tablets of 12.5 mg and 14 tablets of 25 mg, totaling 28 days supply. Manufactured and distributed by SK Life Science, Inc.*

FDA Label Image

50 mg 14-count And 100 mg 14-count Titration Pack Label (Cenobamate 10)

A dosing schedule and usage instructions for Xcopri (cenobamate) tablets, showing a weekly blister pack layout with days numbered 1 to 28. The dosing schedule increments tablets from 12.5 mg in weeks 1 and 2, to 25 mg in weeks 3 and 4. Instructions include taking 12.5 mg orally once daily for two weeks, then 25 mg daily for two weeks, with illustrations for how to push pills through foil. Storage, dosage, and ingredients information is also provided.*

FDA Label Image

50 mg 14-count And 100 mg 14-count Titration Pack Label (Cenobamate 11)

Packaging label for Xcopri (cenobamate tablets) oral film-coated tablets. This is a titration pack containing 50 mg (14 tablets) and 100 mg (14 tablets) strengths, designed for a 28-day period. The label highlights the titration dosing instructions and features the SK Life Science, Inc. logo and contact information. NDC 71699-202-28 is visible along with a barcode and QR code.*

FDA Label Image

150 mg 14-count And 200 mg 14-count Titration Pack Label (Cenobamate 12)

An illustrated medication guide for Xcopri (cenobamate) tablets showing dosage instructions, storage, and tablet ingredients. The guide features a four-week pill calendar with daily push-through doses starting with 50 mg tablets in weeks 1 and 2, then increasing to 100 mg tablets in weeks 3 and 4. Included are step-by-step instructions on how to push the tablet through the blister foil and peel the tab for administration.*

FDA Label Image

150 mg 14-count And 200 mg 14-count Titration Pack Label (Cenobamate 13)

Packaging label for Xcopri cenobamate tablets, a film-coated oral tablet. This titration pack includes 150 mg and 200 mg strengths, with 14 tablets of each strength. Labeler is SK Life Science, Inc. The label features the Xcopri logo, strength information, usage instructions for titration, and NDC 71699-203-28.*

FDA Label Image

200 mg 28 Count And 50 mg 28-count Maintenance Pack (Cenobamate 14)

This image displays dosage and administration instructions for Xcopri (cenobamate) tablets. It includes steps for tablet removal from the blister pack and recommended oral dosing instructions: 150 mg daily for two weeks, followed by 200 mg daily for two weeks. Storage guidance and active ingredient content per tablet are also listed. The blister pack days and dosages for weeks 1 to 4 are visible.*

FDA Label Image

200 mg 28 Count And 50 mg 28-count Maintenance Pack (Cenobamate 15)

Packaging label for Xcopri (cenobamate) tablets, film coated, 250 mg daily dose. The label shows a maintenance pack containing 28 tablets of 200 mg and 28 tablets of 50 mg. It includes the manufacturer information, SK Life Science, Inc., with address in Paramus, NJ. The label features purple and white colors with the Xcopri logo and dosage instructions.*

FDA Label Image

150 mg 28-count And 200 mg 28-count Maintenance Pack (Cenobamate 16)

This image shows a partial patient information leaflet for Xcopri (cenobamate tablets) including instructions on use, storage, dosage, and ingredients. It features illustrated steps for removing tablets from blister packaging, storage temperature recommendations, and notes on dosing with 200 mg and 50 mg tablets. A logo for Xcopri is visible at the bottom.*

FDA Label Image

150 mg 28-count And 200 mg 28-count Maintenance Pack (Cenobamate 17)

Packaging label for Xcopri (cenobamate tablets) film-coated tablets by SK Life Science, Inc. This maintenance pack contains 350 mg daily dose tablets in a 28-tablet supply. The label includes dosing instructions, manufacturer contact information, and branding with purple and white color schemes.*

FDA Label Image

Cenobamate 18

This image shows partial patient instructions for Xcopri (cenobamate tablets), including how to take the medication, storage conditions, dosage, and ingredients. It features step-by-step graphics on tablet removal from blister packaging. The image also partially displays a multi-week dosing calendar with dates, daily dosage amounts (200 mg and 150 mg), and placeholders for tablet intake tracking.*

FDA Label Image

Cenobamate 19

Packaging label for Xcopri (cenobamate) 250 mg oral film-coated tablets, presented as a maintenance pack. The label includes the proprietary and generic names, dosage form, strength, and active ingredient. It indicates a 28-day supply with 28 tablets per pack. The labeler is SK Life Science, Inc., and the packaging features the Xcopri logo with purple and white color scheme, including outlined tablet shapes.*

FDA Label Image

Cenobamate 20

Dosage and administration chart for Xcopri (cenobamate) tablets showing a 4-week regimen of 150 mg plus 100 mg tablets daily. The panel includes instructions on pill usage, storage conditions, dosage recommendation to see prescribing info, and ingredient amounts per tablet. Illustrations demonstrate how to push pills through the blister foil.*

FDA Label Image

Cenobamate 21

Xcopri (cenobamate tablets) oral film-coated tablets packaging label for a titration pack containing 12.5 mg and 25 mg strengths. The label identifies the product as a professional sample, not for sale, and includes directions for titration dose escalation. It is manufactured by SK Life Science, Inc. and contains 14 tablets of each strength for a total 28-day supply. The packaging displays the NDC 71699-999-99 and states Rx only.*

FDA Label Image

Cenobamate 22

An illustrated dosing calendar for Xcopri (cenobamate) tablets, film coated, showing a 28-day schedule with weekly dosage increments. Weeks 1 and 2 indicate 12.5 mg per tablet, while weeks 3 and 4 indicate 25 mg per tablet. Each day is numbered from 1 to 28, with corresponding push-through blister pack outlines for each dose, organized in four weekly columns.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.